Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05731141 · ClinicalTrials.gov registry record
A Prospective Natural History Study of Lymphatic Anomalies
A clinical trial of Lymphatic Diseases and Lymphatic Abnormalities, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 2
- Study locations
NCT05731141: Recruiting study of Lymphatic Diseases and Lymphatic Abnormalities, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
NCT05731141 is a study of Lymphatic Diseases and Lymphatic Abnormalities that is actively recruiting participants, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 1,200 participants, above the 64-participant average among 6 other Lymphatic Diseases trials with a reported enrollment target (1775% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05731141, a study of Lymphatic Diseases and Lymphatic Abnormalities, is actively recruiting participants, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: The lymphatic system is a network of vessels that carry a clear fluid called lymph through the body. Problems in the lymphatic system can cause pain, fluid buildup, and issues with immunity. There is much researchers do not understand about lymphatic anomalies. In this natural history study, they will collect data from a lot of people over a long time. Objective: To better understand why lymphatic anomalies develop. The goal is to improve future treatments. Eligibility: People aged 0 days and older with a suspected or confirmed lymphatic anomaly. Their unaffected parents or siblings aged 7 years or older are also needed. Design: Participants may remain in the study indefinitely. Affected participants may be evaluated every 10 months to 2 years. Some participants will be seen over telemedicine. Others will be seen at the NIH Clinical Center for 2-5 days. All participants will have a physical exam. They may provide specimens including blood, saliva, hair follicles, stool, skin, and other tissues. Samples may be used for genetic testing. Participants may undergo other tests depending on their medical conditions. The NIH Clinical Center visit may include: Heart tests include placing stickers on the chest to measure electrical activity and using sound waves to capture pictures of the heart. A lung test measures the muscle strength in the chest. Participants will blow into a tube. Photographs may be taken of participants faces and other features. Imaging scans will take pictures of the inside of the body. One scan will measure bone density. One type of scan tracks how lymph fluid moves through the body. Participants will be under anesthesia, and they will be injected with a dye.
Primary Outcome
We plan to enroll a group of participants willing to participate in the study over time.
Conditions Studied
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2028-12-31 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
What NCT05731141 shows while recruiting
NCT05731141 is an observational study that tracks outcomes without assigning an intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 64-participant average among 6 other Lymphatic Diseases trials with a reported enrollment target (1775% higher).
The record links to 2 conditions, with Lymphatic Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT05731141 reports a single indexed study location in Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05731141 about?
NCT05731141 is a clinical study titled "A Prospective Natural History Study of Lymphatic Anomalies". Background: The lymphatic system is a network of vessels that carry a clear fluid called lymph through the body. Problems in the lymphatic system can cause pain, fluid buildup, and issues with immunity. There is much researchers do not understand about lymphatic anomalies. In this natural history s...
What is the current status of trial NCT05731141?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2023-03-20. Estimated completion is 2028-12-31.
What conditions does trial NCT05731141 study?
This clinical trial studies the following conditions: Lymphatic Diseases, Lymphatic Abnormalities.
Who is sponsoring clinical trial NCT05731141?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05731141 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphatic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
RECRUITING · NA
-
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
ACTIVE NOT RECRUITING · Phase 1
-
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI